CLINICAL TRIAL SUMMARY

MDACC Study No:2012-0428 (clinicaltrials.gov NCT No: NCT01736683)
Title:AN OPEN-LABEL, RANDOMIZED, PHASE 2, PARALLEL, DOSE-RANGING, MULTICENTER STUDY OF SOTATERCEPT FOR THE TREATMENT OF PATIENTS WITH ANEMIA AND LOW- OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES OR NON-PROLIFERATIVE CHRONIC
MYELOMONOCYTIC LEUKEMIA (CMML)
Principal Investigator:Guillermo Garcia-Manero
Treatment Agent:Sotatercept – ACE-011
Study Status:Open
Study Description:The goal of this clinical research study is to find the most effective dose of
sotatercept to treat MDS or non-proliferative CMML. The safety of the drug
will also be tested.

Sotatercept may increase red blood cell counts and improve the anemia that is a
symptom of MDS.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Sotatercept – ACE-011
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Celgene
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Guillermo Garcia-Manero
Dept:Leukemia
For Clinical Trial Enrollment:713-745-3428
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults